Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)

HIV Medicine

Volumn 12, Issue 10, 2011, Pages 602-609

  Feeney, E R ^a   Chazallon, C ^b   O'Brien, N ^a   Meiffredy V ^b   Goodall, R L ^c   Aboulker, J P ^b   Cooper, D A ^d   Yeni, P ^e   Mallon, P W G ^a,f  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b INSERM   (France)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e France   (France)

^f MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Didanosine; Lactic acidosis; Mitochondrial DNA; Stavudine; Symptomatic hyperlactataemia

Indexed keywords

DIDANOSINE; EFAVIRENZ; LACTIC ACID; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; NELFINAVIR; STAVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FATIGUE; FEMALE; FOLLOW UP; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATIC HYPERLACTATEMIA; VOMITING; WEIGHT REDUCTION;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; AUSTRALASIA; BODY MASS INDEX; DIDANOSINE; DNA, MITOCHONDRIAL; DNA, VIRAL; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NORTH AMERICA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RNA; RNA, VIRAL; SEX FACTORS; SOUTH AMERICA; STAVUDINE;

EID: 80054834564     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00934.x     Document Type: Article

References (35)

1. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51-59.
2. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
3. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.
4. Falco V, Rodriguez D, Ribera E et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838-846.
5. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21: 2455-2464.
6. John M, Moore CB, James IR et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
7. Moyle GJ, Datta D, Mandalia S et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341-1349.
8. Sheng WH, Hsieh SM, Lee SC et al. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan. Int J STD AIDS 2004; 15: 249-253.
9. Wester CW, Okezie OA, Thomas AM et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46: 318-322.
10. Nguyen A, Calmy A, Schiffer V et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9: 142-150.
11. Stead D, Osler M, Boulle A, Rebe K, Meintjes G. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther 2008; 13: 937-943.
12. Walker UA, Bauerle J, Laguno M et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-317.
13. Chapplain JM, Beillot J, Begue JM et al. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. J Acquir Immune Defic Syndr 2004; 37: 1477-1488.
14. Thoden J, Lebrecht D, Venhoff N et al. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs. AIDS 2008; 22: 1093-1094.
15. Cote HC, Brumme ZL, Craib KJ et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-820.
16. Cote HC, Yip B, Asselin JJ et al. Mitochondrial: nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187: 1972-1976.
17. Casula M, Bosboom-Dobbelaer I, Smolders K et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005; 191: 1468-1471.
18. Cherry CL, Gahan ME, McArthur JC et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30: 271-277.
19. Maagaard A, Holberg-Petersen M, Kollberg G et al. Mitochondrial (mt) DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11: 601-608.
20. Yeni P, Cooper DA, Aboulker JP et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368: 287-298.
21. WHO. Global Data on Body Mass Index. Available at (accessed 31 January 2011).
22. Mallon PW, Unemori P, Sedwell R et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191: 1686-1696.
23. Mallon PW, Sedwell R, Unemori P et al. Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy. Antivir Ther 2005; 10 (Suppl 2): M101-M108.
24. Cote HC, Gerschenson M, Walker UA et al. Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. Mitochondrion 2011; 11: 520-527.
25. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45: 254-260.
26. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-166.
27. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-196.
28. Geddes R, Knight S, Moosa MY et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96: 722-724.
29. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46: 312-317.
30. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
31. Ritov VB, Menshikova EV, He J et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005; 54: 8-14.
32. Raffaella C, Francesca B, Italia F et al. Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity (Silver Spring) 2008; 16: 958-964.
33. Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79: 340-343.
34. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010; 11: 121-129.
35. Banas B, Kost BP, Goebel FD. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004; 9: 371-377.